DWTX
Dogwood Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.21
−0.82%Oct 19, 2026, 12:53 UTC
Dogwood Therapeutics entered into a registration rights agreement with Sealbond Limited covering resale registration of the shares issued in the private placement.
Oct 19, 2026, 12:53 UTC
Dogwood Therapeutics agreed to sell 4,098,360 common shares to Sealbond Limited in a private placement for $1.22 per share, totaling $4,999,999.20, for general working capital.
Sep 14, 2026, 12:45 UTC
Dogwood Therapeutics completed patient enrollment in its ongoing Phase 2b trial of Halneuron for chemotherapy-induced neuropathic pain, enrolling 239 patients.
Source:Aug 13, 2026, 12:30 UTC
Dogwood Therapeutics announced its financial results for the second quarter of 2026.
Source:Jul 20, 2026, 12:30 UTC
Dogwood Therapeutics enrolled the first 200 patients in its ongoing HAL-CINP Phase 2b trial for Halneuron to treat chemotherapy-induced neuropathy.
Source: